Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025JCI InsightOpen Access

Randomized trial of activated vitamin D for acute kidney injury prevention in critically ill patients

View Full Paper
Ask AI
Bookmark
Share

Authors

DLDavid E. LeafTSTushar ShenoyKZKevin Zinchuk

Discussion

Loading...

Member takes

Implication

Phase 2 trial compared activated vitamin D forms to placebo in critically ill patients, indicating no AKI prevention.

Key Points

  • Activated vitamin D did not prevent acute kidney injury in critically ill adults, despite prior evidence of immunomodulation.
  • In this trial, the primary endpoint showed no significant differences in outcomes between calcifediol and placebo-treated groups (P = 0.85).
  • Randomized, double-blind study involved 150 high-risk patients to assess AKI prevention via multiple doses of vitamin D derivatives.
  • The lack of efficacy may inform future research directions for interventions aimed at preventing acute kidney injury.

Cite This Study

Leaf et al. (2025) studied this question.

synapsesocial.com/papers/68d413f8713b0b5dfea61b14https://doi.org/10.1172/jci.insight.193523
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters2012 · 39,907 citations
  2. 2edgeR v4: powerful differential analysis of sequencing data with expanded functionality and improved support for small counts and larger datasets2025 · 733 citations